Business
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
ALAMEDA, Calif., February 10, 2026--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.
About this update from Ipsen Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1200,"height":327,"url":"https://media.zenfs.com/en/business-wire.com/1070c08c7873fb79dc27184f74c2e8bf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rKZul7EreD0Lhy16Rv7ijw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1070c08c7873fb79dc27184f74c2e8bf","width":960,"height":262},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/m5yOjfBRgfzggr.4kp.jwQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE3NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1070c08c7873fb79dc27184f74c2e8bf","width":640,"height":174},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/jXKDBJXvu25CE13L77ur8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/1070c08c7873fb79dc27184f74c2e8bf","width":1200,"height":327}},"lazy":false},{"type":"text","content":"– Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 –– Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quarter of 2025 –– GAAP Diluted EPS of $0.88 for the Fourth Quarter of 2025, $2.78 for the Fiscal Year 2025 –– Conference Call and Webcast Today at 5:00 PM Eastern Time –","length":421,"tagName":"p","attribs":{}},{"type":"text","content":"ALAMEDA, Calif., February 10, 2026--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.","length":312,"tagName":"p"},{"type":"text","content":""Exelixis delivered strong results in 2025 and is well positioned for a breakout year in 2026," said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. "The cabozantinib franchise continued to grow with robust demand in renal cell carcinoma and neuroendocrine tumors driving a significant increase in net product revenues in 2025 compared to the prior year. Based on the early success in neuroendocrine tumors and with additional gastrointestinal cancer market opportunities ahead, we’ve expedite...